24 February 2015 - In March of 2013, the number of submissions to the CADTH Common Drug Review (CDR) started to surpass our capacity to conduct the reviews in accordance with established timelines. Over time, this led to a rather extensive backlog of submissions. CADTH is pleased to announce that the backlog of applications for submissions and resubmissions to CDR has been cleared. Going forward, CADTH has a comprehensive risk mitigation strategy in place to prevent the recurrence of a backlog in CADTH’s drug review programs. We will also continue to evaluate and improve our drug review processes to ensure that Canadians benefit from timely, evidence-informed formulary listing recommendations.

For more details, go to: http://www.cadth.ca/en/products/cdr/cdr-update/cdr-update-109?utm_source=CADTH%2FACMTS+Confirmed+Subscribers&utm_campaign=bdefa9d5c2-E_Alert_CDR_Update+109&utm_medium=email&utm_term=0_4df26bdb5b-bdefa9d5c2-197490029